Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib in adults with persistent or chronic ITP who failed second-line therapy
ChiCTR2400083875Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of linperlisib in immune thrombocytopenia (ITP), sponsored by Henan Cancer Hospital. Primary endpoints: Safety and tolerability of linperlisib, Dose-limiting toxicity (DLT) and 1 more. Planned start May 2024; status: not yet recruiting.
02
Drugs
linperlisib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR2400083875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083875.